Objective: Loss of function FTO mutations significantly impact body composition in humans and mice, with Fto-deficient mice reported to resist the development of obesity in response to a high-fat diet (HFD). We aimed to further explore the interactions between FTO and HFD and determine if FTO can influence the adverse metabolic consequence of HFD. Methods: We studied mice deficient in FTO in two well validated models of leptin resistance (HFD feeding and central palmitate injection) to determine how Fto genotype may influence the action of leptin. Using transcriptomic analysis of hypothalamic tissue to identify relevant pathways affected by the loss of Fto, we combined data from co-immunoprecipitation, yeast 2-hybrid and luciferase reporter assays to identify mechanisms through which FTO can influence the development of leptin resistant states. Results: Mice deficient in Fto significantly increased their fat mass in response to HFD. Fto þ/À and Fto À/À mice remained sensitive to the anorexigenic effects of leptin, both after exposure to a HFD or after acute central application of palmitate. Genes encoding components of the NFlB signalling pathway were down-regulated in the hypothalami of Fto-deficient mice following a HFD. When this pathway was reactivated in Fto-deficient mice with a single low central dose of TNFa, the mice became less sensitive to the effect of leptin. We identified a transcriptional coactivator of NFlB, TRIP4, as a binding partner of FTO and a molecule that is required for TRIP4 dependent transactivation of NFlB. Conclusions: Our study demonstrates that, independent of body weight, Fto influences the metabolic outcomes of a HFD through alteration of hypothalamic NFlB signalling. This supports the notion that pharmacological modulation of FTO activity might have the potential for therapeutic benefit in improving leptin sensitivity, in a manner that is influenced by the nutritional environment.
INTRODUCTION
Genome-wide association studies (GWAS) have indicated that single nucleotide polymorphisms (SNPs) on chromosome 16 within the first intron of FTO (FaT mass and Obesity related) are robustly associated with human obesity [1] . These SNPs are also associated with obesityrelated anthropometric traits such as fat mass, leptin levels and waistto-hip ratio, as well as an increase in food intake and a reduction in satiety. More detailed analyses have determined that the increase in consumed energy in risk allele carriers appears due, at least in part, to an increased in preference for energy-dense food, especially those with a higher fat content [2, 3] . FTO is a member of the ALKB family of nucleic acid demethylases and has a high affinity for 3-methylthymine (3-meT) in DNA [4] as well as 3-methyluracil (3-meU; [4, 5] ) and 6-methyladenosine (6-meA; [6] ) in RNA.
The intronic SNPs associated with human obesity may influence adiposity through effects on the expression of other neighbouring genes including IRX3 [7] and RPGRIP1L [8] . Whatever the explanation for the effects of intronic polymorphism on human adiposity, studies of humans and mice carrying genetic variants that functionally perturb FTO indicate that FTO itself is an important regulator of body size and composition, with loss of function mutations being associated with low body weight in humans [9] and mice [10, 11, 12] and transgenic overexpression resulting in obesity in mice [13] . Fto is highly expressed within the hypothalamus [1, 4] and Fto mRNA levels in the arcuate nucleus are reduced by fasting [4, 14, 15] and increased by high-fat feeding [15, 16] . Notably, Fto þ/À and Fto À/À mice have been reported to be protected from the development of obesity on a high-fat diet (HFD) [10] while high-fat feeding exacerbates the obesity of mice overexpressing Fto [13] . 1 The concept of "leptin resistance" has emerged to explain why obese animals, with high circulating leptin levels, do not appear to demonstrate the anorectic effects of leptin that are present in lean animals. High-fat feeding is a classical model whereby resistance to leptin can be induced in an experimental model. This can be replicated acutely by the central infusion of fatty acids, including palmitate [17] . More recently the notion has emerged that high-fat feeding and high central exposure to lipids can induce a state of inflammation in the hypothalamus and that this might be an important part of the induction of leptin resistance [18] . In this study, we provide further evidence that Fto þ/À and Fto À/À mice remain sensitive to the anorectic effects of leptin despite exposure to either a HFD or the acute central administration of palmitate. We also identify a transcriptional co-activator that physically and functionally interacts with FTO to activate hypothalamic NFlB signalling pathways that have previously been implicated in the pathogenesis of leptin resistance.
MATERIAL AND METHODS

Mice
Fto deficient mice were a generous gift from Prof. Roger Cox (MRC Harwell, Oxford) and were generated and genotyped as previously described [12] . All mice were maintained under controlled temperature (22 C) and on a 12hr light, 12hr dark schedule (light on 07:00e 19:00). Food and water were available ad libitum unless otherwise stated. All mice were weaned at 3 weeks of age onto a standard chow (SDS RM3, Essex, UK). All protocols were in accordance with the United Kingdom Home Office legislation (Animal (Scientific Procedure) Act 1986).
Dietary intervention
Standard chow throughout all studies was SDS RM3 (Essex, UK). High fat diet used contains 60% of calories from fat, 20% from protein and 20% from Carbohydrate (D12492, Research Diet).
Body composition analysis
Body composition was determined using dual-energy X-ray absorptiometry (DEXA, PIX-Imus2 Series Densimeters) under terminal anaesthetic (Dolethal, Vetoquinol UK Ltd).
Glucose homeostasis
Oral glucose tolerance test (OGTT; 2 g glucose/kg) was performed in mice that were fasted for 6 h (beginning at 8AM) following 5 weeks on a HFD. Briefly, a bolus of 20% glucose was delivered into the stomach by a gavage needle and blood for measurement of glucose was taken by tail vein sampling at 0, 10, 20, 30, 60, 90 and 120 min and assayed with a glucometer (AlphaTRAK2, Abbott Animal Health).
Intracerebroventricular experiments
To allow ICV injection, male mice aged between 10 and 13 weeks underwent stereotaxic surgery to place an indwelling guide cannula into the lateral ventricle. Mice were anaesthetised with a mix of inhaled isofluorane and oxygen and a 26 gauge steel guide cannula (internal diameter 0.24 mm, outer diameter 0.46 mm, length 2 mm; Semat International, UK) was implanted into the right lateral ventricle using the following coordinates: 1.0 mm lateral from bregma, 0.5 mm posterior to bregma; 2.0 mm depth. The guide cannula was secured to the skull using quick-drying cyanoacrylate glue and dental cement (Associated Dental Products, Wiltshire, UK), and a dummy cannula was inserted. All animals received analgesia (Rimadyl, 5 mg/kg, Pfizer Animal Health, Kent, UK) and antibiotic (Teramycin LA, 60 mg/kg, Pfizer Animal Health, Kent, UK) before being returned to their home cage. Following surgery, mice were single housed throughout the study, food intake and body weight was measured daily. Injections were performed while mice were in their home cages and food returned 60 min after the last injection.
2.2.1. Leptin responsiveness 8 week old male mice of each genotype were given either standard chow diet or HFD for four weeks, and had indwelling guide cannula placed as described above. Seven days post-surgery mice were reassessed and only those that had remained weight stable or put on weight were studied. After an overnight fast, mice received either 2 ml of PBS or recombinant murine leptin (500 ng in 2 ml; Amgen) via the cannula. Standard chow or high-fat diet was returned to the hopper and the amount consumed after 4-and 24-hr was measured.
2.2.2. Palmitate injection 10e13 week old male mice maintained on standard chow were used.
Mice were fasted overnight and 1 ml of each injectant or corresponding vehicle control was injected according to the respective experimental set-up (Figures 3 & 5) . A crossover design was used such that each mouse served as its own control. Animals were allowed a washout period of at least 5 days between treatments and the order of treatments were re-randomized between experiments. Stock solution of 3.3 mM palmitate (Cat. 76119, Sigma) was prepared with 100% EtOH at 60 C and further diluted with fatty acid-free BSA (Cat. A6003, Sigma) to give a final concentration of 66uM/ml. BSA or PBS Saline vehicle injectants were prepared equivalently, but without palmitate or recombinant mouse TNFa (aa 80e235; R & D System), respectively.
Immunohistochemistry
Adult male mice were deeply anesthetised with sodium pentobarbital and were transcardially perfused with PBS followed by ice-cold 10% formalin. After perfusion, brains were removed and post-fixed in 15% sucrose formalin then transferred to 30% (wt/vol) sucrose in PBS overnight. Perfused brains were sectioned at 30 mm thickness on a microtome in a one-in-four coronal series through the hypothalamus. Phosphorylated STAT3 immunohistochemistry was performed as previously described [19] [20] . After the IPs, immunocomplexes were eluted using glycine buffer (pH 3.0) at 4 C for 30 min. After the elution remaining beads and eluate were resuspended in 1x sample buffer for Western blot analysis.
Luciferase assays
For the luciferase study, assays were performed with the Cignal NFkB Reporter Assay (Promega). Briefly, MEF cells derived from Fto null mice were transfected with the Cignal reporters which is a mixture of an inducible NFkB-responsive firefly luciferase construct and a constitutively expressing renilla luciferase construct, together with various combinations of expression vectors under investigation. "Empty" vector controls expresses GFP and was also used to monitor consistency in transfection efficiency. All transfections were performed with the Neon transfection system (Invitrogen), following the manufacturer's instructions, and enzymatic activities were measured using a luminometer (DLReady; Berthold Technologies) performed with the Dual-luciferase reporter system (Promega). Briefly, firefly luciferase reagent (LARII) was added to the test sample followed by addition of equal amounts of renilla luciferase reagent and firefly quenching reagent (Stop & Glo). The data are represented as the ratio of firefly to renilla luciferase activity and is the mean of at least three separate experiments performed in triplicate.
2.7. Testing of the direct in vivo interaction between FTO and TRIP4 in the Y2H system Yeast two-hybrid is a widely used method for studying proteineprotein interactions in vivo, so we used the commercially available Matchmaker Gold Yeast Two-Hybrid System (Clontech). In these assays, FTO is expressed as a fusion to the GAL4 DNA-binding domain (BD), while TRIP4 is expressed as fusion to the GAL4 activation domain (AD). When FTO and TRIP4 fusion proteins interact, the DNA-BD and AD are brought into close proximity, thus activating transcription of four independent reporter genes (AUR1-C, ADE2, HIS3 and MEL1). The combination of antibiotic, nutritional and colorimetric reporters means false positive are reduced to a minimal and allow for "grading" of the binding strength to be determined, with activation of all four reporters suggesting the highest binding strength. Nine truncated fragments of the human FTO functional domains were tested for their ability to bind to the full length TRIP4 directly. All of the procedures were performed according to the manufacturer's protocol (Clontech). Briefly, full length or truncated constructs of FTO were cloned into the vector pGBKT7 and were used to transfect the yeast strain AH107 and the pGADT7-TRIP4 recombinant plasmids were transfected into the yeast strand Y180. The yeast strains Y187-pGADT7-TRIP4 and AH109-pGBKT7-FTO were tested for autonomous activation, and none of the constructs showed any selfactivation. The transfected strains were used for the yeast twohybrid mating assays testing the binding domains for interaction between FTO and TRIP4. The "mated" transformants were cultured in medium for 20hr and then plated onto the appropriate selective medium. The strength of the interaction was confirmed by colonies growing on the selective medium, with the highest binding denoted as "þþþþ" assigned to colonies growing on fully selective medium; while "À" was assigned to background colony growth. All data presented are repeats of at least 3 separate experiments and most of the interactions were done with TRIP4 cloned into the vector pGADT7 (containing AD) and FTO cloned into vector pGBKT7 (containing BD); but for a selection of interaction studies, the reverse were also assayed to eliminate potential bias and the obtained results were comparable in either cloning direction.
Statistical analysis
All data are presented as mean AE SEM and have been analysed using Microsoft Excel and GraphPad Prism 5. Single comparisons were made using one-or two-tail Student's t-test as specified in the respective figure legends. Multiple comparisons were tested with ANOVA and adjusted with Bonferroni's post-test. Difference among groups were considered significant for p-values of <0.05.
RESULTS
3.1. Influence of Fto status on the change of body composition in response to a HFD We were intrigued by the previous reports that Fto-deficient and haploinsufficient mice did not develop obesity in response to a high-fat diet [10] and initially set out to see if this phenomenon was readily replicable. Eight week old WT, Fto þ/À and Fto À/À mice were given a 60%
HFD for five weeks and their body composition subsequently compared to age-matched mice of the same genotypes that had been continuously provided with regular chow for the same time period. As previously reported, on regular chow Fto À/À mice had a significant reduction in total body weight ( Figure 1A ), fat mass ( Figure 1B ) and lean mass ( Figure 1C ), as well as bone mineral density ( Figure 1D ), when compared to WT littermates. As expected, after five weeks on HFD diet, WT mice weighed 44% more than mice fed chow (40.1 AE 1.5 g vs 27.9 AE 0.6 g; p < 0.001) ( Figure 1A Figure 3A) . As expected, pre- mice, although this was not statistically significant ( Figure 3C ).
3.4. NFkB signalling pathway is down-regulated in Fto-deficient mice on HFD We looked next to determine the underlying molecular mechanism that allow Fto-deficient mice to remain leptin sensitive on a HFD by examining gene expression within the hypothalamus, a region critically involved in appetite regulation and one in which Fto is highly expressed (Supplemental Figure 9) . Analysis of canonical leptin responsive genes within the ARC showed no differences in expression of Agrp, Npy, Figure 4A ).
We turned next to the pathways downstream of the leptin receptor. Leptin signalling via STAT3 induces the expression of SOCS3 mRNA in the hypothalamus, which inhibits the phosphorylation and activation of JAK2. Over-activation of SOCS3 is a proposed mechanism for leptin resistance; particularly in diet induced obese states. We found a significant reduction in Socs3 expression in the hypothalami of Fto deficient mice on a HFD as compared to WT mice ( Figure 4A & Supplemental Figure 4B ). In addition to playing a role in leptin signalling, SOCS3 is also downstream of NFlB signalling, a pathway known to be up-regulated within the medial-basal hypothalamus in response to a HFD. We measured expression of Myd88, a key adapter required for NFlB activation, and found that it too exhibited a significant reduced response in Fto deficient mice on a HFD as compared to WT mice ( Figure 4A & Supplemental Figure 4B ). These findings prompted us to examine the NFlB pathway more broadly and using a mouse NFlB signalling pathway profiler PCR array, we measured the gene expression profile of 84 components of NFlB signalling within the hypothalami of WT, Fto þ/À and Fto À/À mice on chow and HFD. The array included genes that encode members of the NFlB, IkB families, NFlB-responsive genes, extracellular ligands and receptors that activate the pathway, as well as downstream kinases and transcription factors. We found no difference in expression pattern of NFlB pathway genes in the three different genotypes on a chow diet (Supplemental Figure 5A) , while, as expected, there was upregulation of 60 NFlB pathway genes in the hypothalami of WT mice exposed to a HFD (Supplemental Figure 5B & Supplemental Table 1 ). However, in Fto-deficient mice on HFD, we found a co-ordinate downregulation of the NFlB pathway in a gene dosage dependent fashion, with Fto À/À mice displaying a greater effect than that seen in Fto Table 2 ). This co-ordinated downregulation of NFlB pathway gene expression was specific to the hypothalamus and was not seen in other regions of the brain such as the cortex and cerebellum, or in peripheral tissues such as epididymal fat and skeletal muscle (Supplemental Figure 6 ). In addition to the NFlB pathway, we also examined expression of a number of key markers of endoplasmic reticulum stress (ER stress), another cellular process that can cause inflammation during HFD feeding and has been suggested to lie downstream of Myd88 signalling [21] . However, no differences in expression were detected in several of the markers of ER stress activation [22] between Fto À/À and WT mice (Supplemental Figure 4C ).
TNFa activation of the NFlB pathway in Fto-deficient mice restores palmitate induced leptin resistance
To establish if down-regulation of the hypothalamic NFlB pathway was causally related to the demonstrated leptin sensitivity, we used centrally administered TNFa to reactivate the pathway in Fto-deficient mice prior to fatty acid administration ( Figure 5 ). Central TNFa treatment has previously been shown to activate the NFlB pathway in the hypothalamus [23] . A dose of TNFa (10 pg) was used that had no effect on 24hr food intake (saline vs TNFa, Fto þ/À 7.7 AE 0.4 g vs 6.2 AE 0.7 g, N.S; Fto À/À 7.1 AE 0.4 g vs 7.9 AE 0.3 g, n.s.) but up-regulated Nfkb2, Myd88, Tlr4 and Socs3 expression in the hypothalami of Fto þ/À and Fto À/À mice (Supplemental Figure 7) . In contrast to the PBS control treatment ( Figure 5A ,B), TNFa pretreatment resulted in sensitization of the Fto À/À mice to palmitate, leading to a blunted response to leptin ( Figure 5B ), similar to that seen in the WT mice, where palmitate prior to leptin injection induced central leptin resistance ( Figure 3A) . In Fto þ/À mice, where NFlB pathway Table 2 ), treatment with TNFa alone was sufficient to induce leptin resistance without palmitate treatment ( Figure 5A ). Thus our data suggest that Fto influences the ability of a HFD to induce central leptin resistance through alteration of hypothalamic NFlB signalling.
3.6. FTO binds to TRIP4 and is necessary for TRIP4 dependent transactivation of NFlB We looked next for interacting partners to determine a possible mechanistic link between FTO and NFlB signalling. Based on bioinformatic analysis of FTO's phylogenetic evolution, we focused on a family of proteins that contained ASCH domains. Although FTO homologues exist in vertebrates and in marine algae, FTO of several algae has an additional C-terminal ASCH domain (Supplemental Figure 8A ). It is a common observation that domains that are components of one polypeptide in some species and separated in different chains in other species enter the same functional pathway, and frequently physically interact [24] . There are only three ASCH domaincontaining proteins in the mammalian genome, one of which is Thyroid receptor interacting protein 4 (TRIP4), a known transcriptional coactivator of NFlB [25] . Trip4 is highly expressed in the CNS, particularly the hypothalamus (Supplemental Figure 9) . We first showed in HEK cells transiently transfected with FLAG tagged FTO, that FLAG antibodies were able to co-immunoprecipitate TRIP4 ( Figure 6A immunoreactive arcuate nucleus neurons with n ¼ 3 mice per group. 3V ¼ third ventricle; ME ¼ median eminence. Bar ¼ 100um. Data are presented as mean AE SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS ¼ not significant following two-tailed t-test.
To confirm a direct interaction between FTO and TRIP4, we undertook an orthogonal approach using the widely used method for studying proteine protein interactions in vivo, the Yeast-2-hybrid (Y2H) system. By determining the interaction of full length human TRIP4 with different deletion mutants of FTO, we showed that amino acid residues 30e48 and 249e 269 in FTO are the epitopes that directly interact with TRIP4 ( Figure 6C ). In the 3-dimensional structure, FTO binds to TRIP4 through two surface mobile epitopes exposed at one side of FTO (Supplemental Figure 8B ).
To determine if FTO and TRIP4 functionally interact to influence the NFlB pathway, we used MEFs obtained from Fto À/À mice and transiently transfected these with an NFlB-responsive luciferase reporter. To this we additionally transfected a TRIP4 expression construct together with a variety of constructs expressing tagged full-length FTO or deletion mutants. The MEFs expressing either FTO or TRIP4 individually, or expressing TRIP4 and N-or C-terminal FTO deletion mutants, did not show an increase in luciferase signal. However, when TRIP4 was expressed with either FLAG-tagged or Myc-tagged full length FTO, there was up to a five-fold increase in luciferase signal ( Figure 6D ). Thus, in the context of this cellular system, FTO appears to be necessary for TRIP4-dependent transactivation of NFlB.
DISCUSSION
We report that mice deficient in Fto significantly increase their fat mass in response to HFD and that Fto þ/À and Fto À/À mice remain sensitive to the anorexigenic effects of leptin, both after exposure to a HFD or after acute central application of palmitate. We show that genes encoding components of the NFlB signalling pathway are down-regulated in Ftodeficient mice following a HFD. Further, when this pathway is reactivated in Fto-deficient mice with a single low central dose of TNFa, the mice became less sensitive to the effects of leptin. We identify a transcriptional coactivator of NFlB, TRIP4, as a binding partner of FTO and a plausible candidate involved in mediating this phenomenon.
Our results are in contrast to the initial report by Fischer and colleagues [10] , where losing just one functional copy of Fto was reported to protect animals from weight gain on a HFD. This difference could be due to the diet used in our study, which contained 60% of its calories from saturated fat, mostly derived from lard, whereas a diet with 42% of calories from milk-fat was used in the previous report. Further differences in the phenotype may be due to different gene targeting strategies, with Fischer et al. deleting exons two and three of Fto, whereas the model we report here only has exon 3 deleted. We also report that despite a lowered fat mass in the Fto null mice, there was no difference in serum leptin levels between the three genotypes, either on regular chow or after a HFD. The determinants of circulating leptin levels are complex, not fully understood and not wholly determined by leptin sensitivity in the hypothalamus. At any given level of fat mass circulating leptin levels vary widely [26] . This is true even in conditions such as leptin receptor deficiency, where the cause of the leptin resistance is known [27] . Interestingly, transgenic mice carrying additional copies of Fto, in whom fat mass is increased, actually show relative hypoleptinemia [13] suggesting that Fto gene dosage may have an effect on leptin levels independent of its effect on fat mass. Intriguingly, in spite of significant weight gain following the HFD, we show that losing just one functional copy of Fto was sufficient to ameliorate the leptin resistance and impaired glucose homeostasis normally associated with exposure to a HFD and an increase in fat mass. Previously, palmitoyl-coA has been shown to accumulate in the hypothalamus of animal models following a HFD [28] and central administration of palmitate leads to leptin resistance [17] . Mice that were completely or partially deficient in Fto were resistant to the effects of central palmitate infusion on leptin's action on food intake. Hypothalamic leptin resistance has been reported in both rats and mice within one to three days of exposure to HFD and prior to substantial weight gain [29] . In our study we showed that the loss of Fto ameliorates the development of central leptin resistance following a highfat challenge. Of note, the HFD also engendered a differential distribution of fat between visceral and subcutaneous depots that mirrored the improved metabolic phenotype observed in FTO deficient mice [30] . This maybe as a result of a role for FTO in fat, with FTO variants having been shown to be associated with both waist circumference and BMI [1] , [31, 32] , as well as leading to a variation in the distribution of adipose tissue as determined by magnetic resonance imaging [33] ; although this has not been directly addressed here. Further, this differential adipocyte phenotype may also have, in part, impacted upon the persistent leptin sensitivity seen in the HFD fed Fto-deficient mice. However, given the fact that leptin sensitivity was also seen in the acute palmitate treated mice, we believe that the effect is due primarily, if not wholly, to central signalling of FTO. It is well-known that central leptin signalling can modulate glucose homeostasis [34e36]. The concept of hypothalamic 'microinflammation', or more accurately the up-regulation of inflammatory markers within the medial basal hypothalamus, is now recognized as a potentially important process in the pathogenesis of HFD induced metabolic disorders [37] . For instance, there are data indicating high-fat feeding can influence leptin sensitivity, through the up-regulation of the Tlr4 [21] , Myd88 [17] , Socs3 [38] and Ptp1b [39] in the hypothalamus which consequently impacts upon metabolic phenotypes [40, 41] . Further, pharmacological or genetic disruption of the NFkB pathways have been shown to restore leptin sensitivity and reduce adiposity in diet induced obesity [18] . Consistent with these studies, we demonstrate here that the consumption of a HFD by WT mice causes an up-regulation of genes in the NFkB pathway in the hypothalamus. This response is significantly reduced with Fto-deficiency in a gene dose-dependent manner.
No difference in leptin sensitivity or NFkB signalling transcription profile was observed when mice were on standard chow, which is to be expected if NFkB is the plausible downstream mechanism for the resistance to leptin observed upon a HFD challenge. NFkB and its upstream regulator IKKb, are both expressed abundantly in the medial basal hypothalamus, remain suppressed under chow conditions and are activated by states of over-nutrition, including HFD and acute central overload of fatty acid and glucose [18] . This mirrors the nutritional regulation of Fto mRNA within the medial basal hypothalamus; being down-regulated by fasting [4, 14, 15 ] and up-regulated by feeding [42] and a HFD [15] , [16] . A low dose of central administration of TNFa has been shown previously to be able to mimic some of the molecular changes seen within the hypothalamus after exposure to a HFD [21, 23, 43] . Our results show that the activation of NFkB signalling by low dose of TNFa restores the ability of palmitate to induce hypothalamic leptin resistance in Fto-deficiency, suggesting that Fto interacts with key molecules Original article 296 along the NFlB pathways to play a role in regulating central leptin sensitivity. Our data suggest that FTO could be a key molecular mediator of leptin resistance and lowering or inhibiting FTO activity may be a plausible therapeutic strategy to improving and/or preserving leptin sensitivity in obese states. The domain composition of FTO in vertebrates and several algae pointed us towards TRIP4, a transcriptional co-activator of NFkB, as a possible mediator of this phenomenon. Our evidence of physical and functional interaction between FTO and TRIP4 suggests a possible mechanism linking FTO to NFkB signalling. Consequently, the upregulation of Fto on a HFD appears to play a key role in the development of leptin resistance. Interestingly, the brain is the only organ that expresses high levels of both Fto and Trip4. Additionally, the coordinated down-regulation in NFkB gene expression between WT and Fto-deficient mice on a HFD is restricted to the hypothalamus, and is not observed in other brain regions or in the periphery. Our data also indicate that loss of Fto signalling specifically impairs HFD-induced NFkB activation while TNFa-induced NFkB activation appears to remain intact. Within the hypothalamus Fto is clearly not the sole activator of NFkB. Rather, our data indicate that FTO regulates NFkB gene expression specifically within the hypothalamus, with other brain regions and peripheral tissues unaffected. We hypothesize that the interaction with TRIP4 within the hypothalamus provides this specificity. Implicating FTO as being able to functionally interact with the NFkB signalling pathway adds another role to an increasing list of putative functions for this molecule. Fto has been characterized as a demethylase with the ability to remove 3 methyl groups from single stranded nucleic acids [4] . More recent evidence indicates that Fto may also have a role in the sensing of amino acids [20] , which potentially provides an explanation for the significant interaction observed between FTO genetic variation and dietary protein on appetite and food cravings [44] . How and if these mechanisms link back into the original observations of associating genomic variance around the FTO locus with human pathophysiology remains to be fully determined. Indeed, recent data focussing on obesity associated variants within FTO have implicated two neighbouring genes, RPGRIP1L and IRX3, as having a functional link between the SNP and the observed human phenotypes. As with Fto, perturbing the expression of these genes in mice results in a bodyweight phenotype, with homozygous deletion of Irx3 resulting in a smaller mouse [7] while heterozygous deletion of Rpgrip1l leading to a mild obesity phenotype [8] . These studies have led to much discussion as to which of the genes close to the loci identified by the initial wave of GWAS are responsible, either wholly or partially, for association with a range of human phenotypic characteristics [45, 46] . The most parsimonious explanation is that a number of genes in this region play an important role in determining body composition. This emerging body of work illustrates the complex biology that can emerge from the deeper exploration of the basis for genomic variants robustly associated with human adiposity. Whatever the contribution of FTO itself to the influence of the polymorphisms within its first intron to human adiposity, it is clear that disturbance of the expression and function of FTO can influence the relationship between dietary composition and fat accumulation, and this supports the notion that pharmacological modulation of the activity of FTO might have the potential for therapeutic benefit in a manner that is influenced by the nutritional environment.
